X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs SUN PHARMA - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD SUN PHARMA ORCHID PHARMA LTD/
SUN PHARMA
 
P/E (TTM) x -0.2 37.1 - View Chart
P/BV x 0.2 4.0 4.0% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 ORCHID PHARMA LTD   SUN PHARMA
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
SUN PHARMA
Mar-18
ORCHID PHARMA LTD/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs194701 27.7%   
Low Rs35433 8.1%   
Sales per share (Unadj.) Rs276.5110.4 250.4%  
Earnings per share (Unadj.) Rs-79.211.0 -721.6%  
Cash flow per share (Unadj.) Rs-43.517.2 -252.2%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs53.9158.8 34.0%  
Shares outstanding (eoy) m70.452,399.26 2.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.45.1 8.1%   
Avg P/E ratio x-1.451.6 -2.8%  
P/CF ratio (eoy) x-2.632.9 -8.0%  
Price / Book Value ratio x2.13.6 59.5%  
Dividend payout %018.2 0.0%   
Avg Mkt Cap Rs m8,0671,360,021 0.6%   
No. of employees `0002.817.8 15.7%   
Total wages/salary Rs m2,52753,671 4.7%   
Avg. sales/employee Rs Th6,956.114,890.9 46.7%   
Avg. wages/employee Rs Th902.53,017.1 29.9%   
Avg. net profit/employee Rs Th-1,993.01,480.6 -134.6%   
INCOME DATA
Net Sales Rs m19,477264,895 7.4%  
Other income Rs m4078,388 4.9%   
Total revenues Rs m19,884273,282 7.3%   
Gross profit Rs m1,10356,081 2.0%  
Depreciation Rs m2,51914,998 16.8%   
Interest Rs m5,2275,176 101.0%   
Profit before tax Rs m-6,23644,295 -14.1%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m511-9,505 -5.4%   
Tax Rs m-1258,452 -1.5%   
Profit after tax Rs m-5,58026,338 -21.2%  
Gross profit margin %5.721.2 26.7%  
Effective tax rate %2.019.1 10.5%   
Net profit margin %-28.79.9 -288.2%  
BALANCE SHEET DATA
Current assets Rs m11,014316,359 3.5%   
Current liabilities Rs m32,060198,643 16.1%   
Net working cap to sales %-108.144.4 -243.2%  
Current ratio x0.31.6 21.6%  
Inventory Days Days9595 100.1%  
Debtors Days Days34108 31.2%  
Net fixed assets Rs m29,440213,178 13.8%   
Share capital Rs m7052,399 29.4%   
"Free" reserves Rs m2,043378,606 0.5%   
Net worth Rs m3,800381,006 1.0%   
Long term debt Rs m9,01817,721 50.9%   
Total assets Rs m46,510643,028 7.2%  
Interest coverage x-0.29.6 -2.0%   
Debt to equity ratio x2.40 5,102.5%  
Sales to assets ratio x0.40.4 101.7%   
Return on assets %-0.84.9 -15.5%  
Return on equity %-146.96.9 -2,124.4%  
Return on capital %-3.710.0 -37.3%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,51340,816 18.4%   
Fx outflow Rs m5,64930,143 18.7%   
Net fx Rs m1,86510,673 17.5%   
CASH FLOW
From Operations Rs m1,68239,072 4.3%  
From Investments Rs m-9,860-33,708 29.3%  
From Financial Activity Rs m6,644-15,393 -43.2%  
Net Cashflow Rs m-1,535-7,359 20.9%  

Share Holding

Indian Promoters % 32.3 63.7 50.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 5.1 89.7%  
FIIs % 3.3 23.0 14.3%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 8.3 666.3%  
Shareholders   84,811 133,026 63.8%  
Pledged promoter(s) holding % 54.9 0.5 10,362.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   WYETH LTD  GSK PHARMA  PANACEA BIOTECH  CIPLA  ABBOTT INDIA  

Compare ORCHID PHARMA LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Down 1%; Realty, Auto Stocks Tank(12:30 pm)

After opening the day flat share markets in India are trading on a negative note and are presently trading below the dotted line.

Related Views on News

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 19, 2018 | Updated on Sep 19, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)

Aug 24, 2018 | Updated on Aug 24, 2018

For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Sep 24, 2018 01:49 PM

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD - ASTRAZENECA PHARMA COMPARISON

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS